Role of magnetic nanoparticles in breast cancer treatment — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/04/140407090226.htm
source : http://www.sciencedaily.com/releases/2014/04/140407090226.htm
source : http://www.sciencedaily.com/releases/2014/03/140326141808.htm
source : http://www.sciencedaily.com/releases/2014/03/140326092558.htm
source : http://www.sciencedaily.com/releases/2014/01/140124111146.htm
The gene-gene interactions underlying CM had not been fully explored. The usual functional model uses substitution of alleles for estimating genetic effects but the estimators are confounded. The NOIA model estimates population effects of alleles and the resulting estimators are orthogonal and no longer confounded. In simulation studies, the NOIA model had higher power for finding interactions and main effects than the usual model. …
Cell division is the process in which cells reproduce by splitting into two identical copies. This process happens trillions of times in an average person’s lifetime…
The specific patient populations who appeared to benefit from eribulin, in comparison to capecitabine, are as follows: Patients with more than two organs involved with metastatic breast cancer Patients who had not received chemotherapy for six months or longer Patients who had received anthracycline and/or a taxane therapies in the metastatic setting Previous pre-specified exploratory analysis of overall survival and progression-free survival showed women with triple-negative, ER-negative, HER2-negative also had a greater relative benefit in overall survival with eribulin over capecitabine. …
Leukemia often occurs due to chromosomal translocations, which are broken chromosomes that cause blood cells to grow uncontrollably. One gene that is involved in chromosomal translocations found at high frequency in childhood leukemia is the MLL1 (Mixed Lineage Leukemia 1) gene. Conventional chemotherapy is very ineffective at curing patients with this translocation, in contrast to other types of childhood leukemia, which are relatively curable. …
Screening for lung cancer using low-dose computed tomography (CT scans) rather than chest X-rays may be a more effective way of detecting the disease, Medscape Today reported. Researchers hope that these results, collected as part of the National Lung Screening Trial, will provide more detailed information about the benefits of various types of lung cancer screening available to patients and physicians. During the study, 26,309 participants received low-dose CT scans, and 26,035 participants underwent chest radiography to detect for signs of lung cancer. Among those who received CT scans, a total of 7,191 participants (27.3 percent) had a positive screening result, compared to 2,387 (9.2 percent) in the chest X-ray group. Overall, lung cancer was diagnosed in 292 participants (1.1 percent) in the CT group compared with 190 (0.7 percent) in the radiography group. Previously, experts had been concerned that the high level of false-positive screenings that occur during CT scans would lead to undue stress, unnecessary testing and high medical bills for patients, Medscape Today reported. However, the new report reveals that the majority of patients who had a positive result after their CT scan only underwent one additional diagnostic test. “In many of the previous analyses people have assumed that there would be three or four or five additional diagnostic tests for every positive screen, and this has ramifications for the cost effectiveness of screening,” study author Dr. William C. Black, professor of radiology at the Dartmouth-Hitchcock Medical Center in Lebanon, N.H., told Medscape Today. Black is hopeful that these results will provide a good frame of reference for other lung cancer screening programs. “If patients and their clinicians are trying to decide whether or not to get screened, they can always refer to these results. They will let patients know what they can expect, what are the likely outcomes, not just in terms of dying of lung cancer, which is only going to happen to a small percentage of people who get screened, but also in terms of the false positives and what happens afterwards,” Dr. Black told Medscape Today. People eligible for lung cancer screening include men and women, ages 55 to 74, who have a 30-pack-per year history of smoking, those who have quit smoking in the last 15 years and those who are medically fit for surgery. Click for more from Medscape Today.source : http://www.foxnews.com/health/2013/05/23/lung-cancer-screening-ct-scans-more-effective-than-x-rays/
CLL lives both in the blood in circulation, and in lymph nodes and bone marrow. The former is relatively easy to kill, but the disease recurs because of resistant CLL cells in the lymph nodes and bone marrow. The researchers found an innovative drug combination that targets the stubborn CLL cells. "We have been studying the mechanism in the cancer cells that causes the resistance to treatment," says Alan Eastman, the senior researcher on the team and a professor of pharmacology and toxicology at the Geisel School of Medicine at Dartmouth, "and that in turn, led us to find drugs that target the resistance." Eastman led the team at Dartmouth-Hitchcock’s Norris Cotton Cancer Center that also included Ryan Soderquist, Darcy Bates, and Alexey Danilov. …